Lilly and SCRI team up to develop investigational oncology therapy
17 June 2015 | By
Lilly and SCRI have entered a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor...
List view / Grid view
17 June 2015 | By
Lilly and SCRI have entered a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor...
17 June 2015 | By Victoria White
The pancreatic cancer treatment pipeline is dominated by early-stage development, meaning many therapies are unlikely to reach the market in the near future...
17 June 2015 | By Victoria White
OncoSec has enrolled the first patient into a Phase II clinical trial of ImmunoPulse IL-12 in patients with squamous cell carcinoma of the head and neck...
17 June 2015 | By Victoria White
Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, has announced the positive outcome of its Phase 1a study with HTL9936...
17 June 2015 | By BIOTECHNICA
The world of medicine is changing fast, and “Personalized Medicine” is a very hot topic...
17 June 2015 | By Victoria White
GARDASIL 9 is approved in the EU for active immunisation against premalignant lesions and cancers affecting the cervix, vulva, vagina or anus...
17 June 2015 | By Victoria White
The FDA has approved ZOMIG Nasal Spray for use in the US in paediatric patients 12 years of age and older for the treatment of migraine with or without aura...
17 June 2015 | By Victoria White
Oncopeptides has presented results from an ongoing study of melflufen with dexamethasone in patients with relapsed and relapsed refractory multiple myeloma...
17 June 2015 | By Victoria White
Preliminary data from a Phase 1/2 trial on Astellas’ ASP2215 were presented at the European Haematology Association annual congress...
16 June 2015 | By Victoria White
Teva has announced positive top-line results from a study designed to evaluate the efficacy of SD-809 in the treatment of tardive dyskinesia...
16 June 2015 | By Victoria White
Rotary has granted $40.3 million to support immunisation activities and research carried out by the Global Polio Eradication Initiative...
16 June 2015 | By Victoria White
Results from a healthy volunteer study investigating the reversal of the anticoagulant effect of Pradaxa by idarucizumab have been published...
16 June 2015 | By Victoria White
The Additive Manufacturing and 3D Printing Research Group (3DPRG) at The University of Nottingham has unveiled its new lab.
16 June 2015 | By Victoria White
The first paediatric patient has begun treatment in Genzyme’s Phase 1/2 clinical trial focused on evaluating the investigational therapy olipudase alfa...
15 June 2015 | By
The US Food and Drug Administration (FDA) has accepted for review Teva’s Biologics License Application (BLA) for reslizumab...